熱門資訊> 正文
礼来公司的Omvoh证明溃疡性结肠炎的肠紧迫感得到改善
2025-10-27 20:16
- Patients with ulcerative colitis who took Eli Lilly's (NYSE:LLY) Omvoh (mirikizumab) saw significant improvements in bowel urgency frequency in a phase 3 trial.
- The LUCENT-URGE study found that by week 12, patients experienced a 55% reduction in daily bowel urgency episodes compared to baseline, and severity cut by more than 50% by week 28.
- Also at week 28, about one-third of patients were able to hold off going to the bathroom for at least 15 minutes after feeling urgency. At baseline, the figure was 4%.
- Lilly noted that Omvoh is being evaluated in ulcerative colitis in two combination studies. One is with eltrekibart (LY3041658), a monoclonal antibody that targets neutrophil-driven inflammation. The other is with LY4268989 (MORF-057), an oral α4β7 integrin inhibitor.
More on Eli Lilly
- Eli Lilly: Is Another Monster Quarter Coming
- Eli Lilly Accelerates On Obesity Data While Novo Nordisk Retreats
- Eli Lilly Vs Novo Nordisk: One To Walk Away From And One To Run Away From
- Earnings week ahead: AAPL, MSFT, AMZN, META, GOOG, BA, XOM, CVX, MA, V, PYPL, SOFI, and more
- Key deals this week: United States Antimony, Grindr, Eli Lilly, Hologic and more
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
